Source: Annual Congress 2005 - Pulmonary hypertension
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. J. Bogaard, R. P. van Steenwijk, P. Bresser (Amsterdam, Netherlands). The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD). Eur Respir J 2005; 26: Suppl. 49, 3608

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD) Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011 Pulmonary rehabilitation (PR) exercise tolerance improvement: Differences between interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013 The composite physiological index strongly predicts mortality in interstitial lung disease (ILD) associated pulmonary hypertension (PH-ILD) Source: International Congress 2017 – Imaging and lung disease PH Year: 2017 Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Effects of pulmonary rehabilitation in patients with interstitial lung disease (ILD) Source: Annual Congress 2009 - New treatment and outcome measures for pulmonary rehabilitation Year: 2009 Benefits of pulmonary rehabilitation (PR) in patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) having the same dyspnoea severity Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients? Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases Year: 2017 Is the severity of oxidative stress different in patients with end stage chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) waiting for lung transplantation? Source: Annual Congress 2007 - Pathophysiology and assessment of COPD Year: 2007 Relationship between pulmonary hypertension (PH) and lung function in severe COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 252s Year: 2001 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 354s Year: 2006 Bosentan treatment in pulmonary arterial hypertension (PAH) associated with interstitial lung diseases (ILDs) Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Time-course changes in pulmonary haemodynamics in patients with idiopathic pulmonary fibrosis (IPF) waiting for lung transplantation (LT) Source: Eur Respir J 2004; 24: Suppl. 48, 668s Year: 2004 Impact of oxygen supplementation on inflammatory response and muscle lesion during high intensity exercise on chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2006 - Muscles, training and rehabilitation Year: 2006 Inflammatory biomarkers in patients with COPD and pulmonary hypertension (PH). Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 A possible role of plasma serotonin (5-HT) and histamin level in pulmonary hypertension (PH) in patients with interstitial lung diseases (ILD) Source: Eur Respir J 2001; 18: Suppl. 33, 416s Year: 2001 Pulmonary hypertension (PH) in chronic hemodialysis (CHD) patients is associated with inflammatory markers and volume overload Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013